Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009) was written by Friedrich, Anita;Olejniczak, Klaus. And the article was included in Regulatory Toxicology and Pharmacology in 2011.Application of 210421-74-2 This article mentions the following:
Carcinogenicity data of medicinal products for human use that have been authorized via the European centralized procedure (CP) between 1995 and 2009 were evaluated. Carcinogenicity data, either from long-term rodent carcinogenicity studies, transgenic mouse studies or repeat-dose toxicity studies were available for 144 active substances contained in 159 medicinal products. Out of these compounds, 94 (65%) were pos. in at least one long-term carcinogenicity study or in repeat-dose toxicity studies. Fifty compounds (35%) showed no evidence of a carcinogenic potential. Out of the 94 compounds with pos. findings in either carcinogenicity or repeat-dose toxicity studies, 33 were pos. in both mice and rats, 40 were pos. in rats only, and 21 were pos. exclusively in mice. Long-term carcinogenicity studies in two rodent species were available for 116 compounds Data from one long-term carcinogenicity study in rats and a transgenic mouse model were available for eight compounds For 13 compounds, carcinogenicity data were generated in only one rodent species. One compound was exclusively tested in a transgenic mouse model. Six compounds were tumorigenic in repeat-dose toxicity studies in rats. The majority of tumor findings observed in rodent carcinogenicity studies were considered not to be relevant for humans, either due to a rodent-specific mechanism of carcinogenicity, a high safety margin between exposures at the NOAEL (No Observed Adverse Effect Level) in rodents and recommended therapeutic doses in humans, or based on historical control data, a small effect size and lack of dose-response relationship and tumors typically observed in rodent strains used, or were considered not to be relevant for humans based on literature and clin. data or likely differences in metabolism/local concentrations between rodents and humans. Due to the high number of rodent tumor findings with unlikely relevance for humans, the value of the currently used testing strategy for carcinogenicity appears questionable. A revision of the carcinogenicity testing paradigm is warranted. In the experiment, the researchers used many compounds, for example, Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2Application of 210421-74-2).
Sodium (4-chloro-3-methylisoxazol-5-yl)((2-(2-(6-methylbenzo[d][1,3]dioxol-5-yl)acetyl)thiophen-3-yl)sulfonyl)amide (cas: 210421-74-2) belongs to isoxazole derivatives.Synthetically, isoxazoles serve as valuable precursors for the construction of diverse molecules, including many natural products. Fe(CO)5 efficiently cleaves the N–O bond of fused isoxazolo-1,4-quinones to give the corresponding imines.All the common reducing reagents failed to open the isoxazole ring.Application of 210421-74-2
Referemce:
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem